Filing Details

Accession Number:
0001209191-18-058222
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-13 16:15:40
Reporting Period:
2018-11-08
Accepted Time:
2018-11-13 16:15:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
914475 Neurocrine Biosciences Inc NBIX Biological Products, (No Disgnostic Substances) (2836) 330525145
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1423837 P. Haig Bozigian 12780 El Camino Real
San Diego CA 92130
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-11-08 19,501 $8.66 155,498 No 4 M Direct
Common Stock Disposition 2018-11-08 19,501 $110.00 135,997 No 4 S Direct
Common Stock Acquisiton 2018-11-08 16,794 $8.65 152,791 No 4 M Direct
Common Stock Disposition 2018-11-08 16,794 $110.00 135,997 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option Acquisiton 2018-11-08 19,501 $8.66 19,501 $8.66
Common Stock Non-Qualified Stock Option Acquisiton 2018-11-08 16,794 $8.65 16,794 $8.65
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,547 2022-01-12 No 4 M Direct
34,376 2023-01-10 No 4 M Direct
Footnotes
  1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
  2. Option granted January 12, 2012 and vested monthly over four years.
  3. Option granted January 10, 2013 and vested monthly over four years.